This meeting took place in the past. Here is a list of meetings that are related:
Web Desc
Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology
Organizer(s): Mark Mercola, Fabien Vincent, Monica Schenone and Arsenio Nueda
Date: March 03 - 07, 2019
Location: Beaver Run Resort, Breckenridge, CO, USA
Sponsored by Merck & Co., Inc. and Pfizer Inc.
Summary of Meeting:
Unlike conventional target-centric drug discovery, Phenotypic Drug Discovery (PDD) places its focus on disease-relevant phenotypes and agnosticism with regard to molecular mechanism of action. Thus, it offers unique opportunities in terms of discovery of novel biology and first-in-class therapeutics but is matched with significant challenges, a number of which can be addressed by recent advances in chemical and systems biology. A key aspect of the conference will be to share information and processes on how best to employ phenotypic strategies to discover novel biology and effectively prosecute drug discovery programs. Specific topics will include: chemical biology advances and case studies in target identification; case studies of recently advanced clinical candidates and approved drugs; functional genomics and systems biology advances and case studies; project prosecution including lessons learned from lead optimization and pre-clinical development; complex cell-based models and new assay modalities. With few non-commercial meetings covering drug discovery as a discipline, this conference has the stature and breadth to bring together accomplished and influential scientists from industry and academia as demonstrated by the 2016 conference. Its scope will be broader than other PDD and Chemical Biology meetings since it will cover the entire range of activities and technologies from phenotypic assay systems, to target identification and FDA approval of novel therapeutics. Given that there is still an emphasis on target centric discovery in pharmaceutical companies, this conference can be instrumental in further promoting a shift in mindset and contributing to the consolidation of PDD as an integral part of the drug discovery paradigm. The vision for this conference would be to share success stories of newly approved drugs and late stage clinical candidates, along with key lessons and best practices, to inform future PDD projects.
Scholarship Deadline: October 30 2018
Discounted Abstract Deadline: October 30 2018
Abstract Deadline: December 4 2018
Discounted Registration Deadline: January 11 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Merck & Co., Inc.Pfizer Inc.
We gratefully acknowledge additional support for this conference from:
Agilent
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Almirall, S.A.

Eurofins DiscoverX

Merck & Co., Inc.

Pfizer Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Center for Advancing Translational Sciences (NCATS)
Grant No. 1R13TR002707-01
Funding for this conference was made possible (in part) by 1R13TR002707-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 03 | 4:00PM - 8:00PM
Arrival and Registration
Room: Colorado Ballroom Foyer


Sunday, March 03 | 6:00PM - 8:00PM
Welcome Mixer
Room: Colorado Ballroom Foyer
No registration fees are used to fund alcohol served at this function.

Monday, March 04 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Monday, March 04 | 8:00AM - 9:15AM
Welcoming Remarks and Keynote Address
Room: Colorado Ballroom
Big picture view of pharmaceutical development, challenges and new opportunities.
Speaker 2 of 2
James E. Bradner, Novartis Institutes for BioMedical Research, USA
Phenotype to Chemotype to Phenotype

Monday, March 04 | 8:00AM - 9:15AM
Welcoming Remarks and Keynote Address
Room: Colorado Ballroom
Big picture view of pharmaceutical development, challenges and new opportunities.
Speaker 1 of 2
* Mark Mercola, Stanford University, USA

Monday, March 04 | 9:15AM - 11:15AM
Clinical Success Stories
Room: Colorado Ballroom
Share success stories - newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.
Speaker 5 of 5
John Tallarico, Novartis Institutes for BioMedical Research, USA
Novel Therapies from Phenotypic Screening

Monday, March 04 | 9:15AM - 11:15AM
Clinical Success Stories
Room: Colorado Ballroom
Share success stories - newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.
Speaker 4 of 5
Fred Van Goor, Vertex Pharmaceuticals Incorporated, USA
Combination Pharmacology to Treat the Underlying Cause of the Majority of People with Cystic Fibrosis

Monday, March 04 | 9:15AM - 11:15AM
Clinical Success Stories
Room: Colorado Ballroom
Share success stories - newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.

Coffee Break

Monday, March 04 | 9:15AM - 11:15AM
Clinical Success Stories
Room: Colorado Ballroom
Share success stories - newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.
Speaker 2 of 5
Yoshihiro Watanabe, Kanazawa University, Japan
Discovery of Trametinib as a MEK-Inhibitor Able to Alter Phosphorylation State of MEK

Monday, March 04 | 9:15AM - 11:15AM
Clinical Success Stories
Room: Colorado Ballroom
Share success stories - newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.
Speaker 1 of 5
* Tom Large, Blue Oak Pharmaceuticals, USA

Monday, March 04 | 11:15AM - 1:00PM
Poster Setup
Room: Breckenridge Ballroom


Monday, March 04 | 11:15AM - 5:00PM
On Own for Lunch


Monday, March 04 | 1:00PM - 10:00PM
Poster Viewing
Room: Breckenridge Ballroom



Monday, March 04 | 2:30PM - 3:30PM
Workshop: Safety De-Risking
Room: Colorado Ballroom

Speaker 3 of 3
* Fabien Vincent, Pfizer Inc., USA
Safety De-Risking in Phenotypic Drug Discovery: Considerations and Strategies

Monday, March 04 | 2:30PM - 3:30PM
Workshop: Safety De-Risking
Room: Colorado Ballroom

Speaker 2 of 3
Ellen L. Berg, Eurofins DiscoverX, USA
Phenotypic Profiling for Toxicity-Associated Signatures Applied to ToxCast Chemicals

Monday, March 04 | 2:30PM - 3:30PM
Workshop: Safety De-Risking
Room: Colorado Ballroom

Speaker 1 of 3
Gerhard Ecker, University of Vienna, Austria
Semantically Integrated Life Science Data – The Power of Workflows for Analysis of Phenotypic Screening Data, Toxicological Read-Across, and Repurposing

Monday, March 04 | 3:30PM - 4:30PM
Panel Discussion
Room: Colorado Ballroom

Speaker 4 of 4
Tom Large, Blue Oak Pharmaceuticals, USA

Monday, March 04 | 3:30PM - 4:30PM
Panel Discussion
Room: Colorado Ballroom

Speaker 3 of 4
Chun-wa Chung, GlaxoSmithKline, UK

Monday, March 04 | 3:30PM - 4:30PM
Panel Discussion
Room: Colorado Ballroom

Speaker 2 of 4
Neil O. Carragher, University of Edinburgh, UK

Monday, March 04 | 3:30PM - 4:30PM
Panel Discussion
Room: Colorado Ballroom

Speaker 1 of 4
Ellen L. Berg, Eurofins DiscoverX, USA

Monday, March 04 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Monday, March 04 | 5:00PM - 7:00PM
New Opportunities and Under-Represented Indications
Room: Colorado Ballroom
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.
Speaker 3 of 6
Clemens R. Scherzer, Harvard Medical School, Brigham and Women's Hospital, USA
Turning Bits and Base Pairs into Precision Neurology

Monday, March 04 | 5:00PM - 7:00PM
New Opportunities and Under-Represented Indications
Room: Colorado Ballroom
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.
Speaker 2 of 6
Lucienne V. Ronco, Fulcrum Therapeutics, USA
Identification of FTX-1821 a Molecule that Inhibits DUX4 Expression and Rescues FSHD Pathophysiology in FSHD Skeletal Muscle Myotubes

Monday, March 04 | 5:00PM - 7:00PM
New Opportunities and Under-Represented Indications
Room: Colorado Ballroom
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.
Speaker 1 of 6
* Jonathan A. Lee, PDD4Patients LLC, USA

Monday, March 04 | 5:00PM - 7:00PM
New Opportunities and Under-Represented Indications
Room: Colorado Ballroom
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.
Speaker 4 of 6
Scott S. Walker, Merck & Co., Inc., USA
Large-Scale Antibacterial Phenotypic Screening and Systematic Hit Triage Reveal Novel Targets and Novel Inhibitors of Established Targets

Monday, March 04 | 5:00PM - 7:00PM
New Opportunities and Under-Represented Indications
Room: Colorado Ballroom
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.
Speaker 5 of 6
Eachan Oliver Johnson, Broad Institute, USA
Short Talk: Large-Scale Chemical-Genetic Interaction Profiling Yields New Classes of Inhibitors of Mycobacterium tuberculosis

Monday, March 04 | 5:00PM - 7:00PM
New Opportunities and Under-Represented Indications
Room: Colorado Ballroom
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.
Speaker 6 of 6
Patrick W. Faloon, Biogen, USA
Short Talk: Identification of Small Molecules that Increase Productive Cellular Processing of Antisense Oligonucleotides (ASOs)

Monday, March 04 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Monday, March 04 | 7:30PM - 10:00PM
Poster Session 1
Room: Breckenridge Ballroom


Tuesday, March 05 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 1 of 9
* Susanne Swalley, Biogen, USA

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 2 of 9
Maurizio Pellecchia, University of California, Riverside, USA
NMR-Based Fragment Screening for Oncology

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 3 of 9
Laura L. Kiessling, Massachusetts Institute of Technology, USA
Glycans in Health and Disease

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.

Coffee Break

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 5 of 9
Razvan L. Cornea, University of Minnesota, USA
Targeting the Pathological Leak of a Calcium Channel for Heart Failure Therapeutics

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 6 of 9
Monica Schenone, Pfizer Inc., USA
Identification of p300/CBP as the Cellular Target of the Small Molecule “BRD16” Following a Phenotypic Screen

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 7 of 9
Sannah Zoffmann, F. Hoffmann-La Roche Ltd., Switzerland
Short Talk: Machine Learning-Powered Antibiotics Phenotypic Drug Discovery

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 8 of 9
Jean-Philippe Coppe, University of California, San Francisco, USA
Short Talk: Mapping Phospho-Catalytic Dependencies of Therapy-Resistant Tumors Reveals New Actionable Vulnerabilities

Tuesday, March 05 | 8:00AM - 11:15AM
Chemical Biology and Novel Molecular Mechanisms of Action
Room: Colorado Ballroom
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Speaker 9 of 9
Julien Olivet, Dana-Farber Cancer Institute, USA
Short Talk: Systematic Assessment of Druggable Cavities in a Histone Deacetylase Complex

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 1 of 8
* Jonathan A. Lee, PDD4Patients LLC, USA

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 2 of 8
Neil O. Carragher, University of Edinburgh, UK

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 3 of 8
Bruce Posner, University of Texas Southwestern Medical Center, USA

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 4 of 8
Veronica Soloveva, Merck, USA

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 5 of 8
Bridget Wagner, Broad Institute, USA

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 6 of 8
Guillermo Vela, NeuScience, USA

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 7 of 8
Arsenio Nueda, Almirall S.A., Spain

Tuesday, March 05 | 11:15AM - 12:15PM
Panel Discussion: Comparing/Contrasting the Practice of PDD
Room: Colorado Ballroom
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining 'buy-in' from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.
Speaker 8 of 8
Christophe Antczak, Novartis Institutes for BioMedical Research, USA

Tuesday, March 05 | 11:15AM - 5:00PM
On Own for Lunch


Tuesday, March 05 | 11:15AM - 1:00PM
Poster Setup
Room: Breckenridge Ballroom


Tuesday, March 05 | 1:00PM - 10:00PM
Poster Viewing
Room: Breckenridge Ballroom


Tuesday, March 05 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Tuesday, March 05 | 5:00PM - 7:00PM
Project Prosecution and Pre-Clinical Advancement
Room: Colorado Ballroom
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.
Speaker 1 of 6
* Scott Wolkenberg, Merck and Co., Inc., USA

Tuesday, March 05 | 5:00PM - 7:00PM
Project Prosecution and Pre-Clinical Advancement
Room: Colorado Ballroom
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.
Speaker 2 of 6
Arsenio Nueda, Almirall S.A., Spain
Harnessing the Power of Phenotypic Screening to Generate Novel Starting Points for Drug Discovery

Tuesday, March 05 | 5:00PM - 7:00PM
Project Prosecution and Pre-Clinical Advancement
Room: Colorado Ballroom
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.
Speaker 3 of 6
Chun-wa Chung, GlaxoSmithKline, UK
Linking Differential Molecular Mode of Action to Distinct Pharmacology

Tuesday, March 05 | 5:00PM - 7:00PM
Project Prosecution and Pre-Clinical Advancement
Room: Colorado Ballroom
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.
Speaker 4 of 6
Derek Lowe, Novartis Institutes for BioMedical Research, USA
Advancement of Phenotypic Hits

Tuesday, March 05 | 5:00PM - 7:00PM
Project Prosecution and Pre-Clinical Advancement
Room: Colorado Ballroom
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.
Speaker 5 of 6
Hassan Javanbakht, Gilead Sciences, USA
Short Talk: Phenotypic Screening in Antiviral Research

Tuesday, March 05 | 5:00PM - 7:00PM
Project Prosecution and Pre-Clinical Advancement
Room: Colorado Ballroom
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.
Speaker 6 of 6
Hassan Al-Ali, University of Miami, USA
Short Talk: Re-Thinking Drug Target Identification and Exploiting Polypharmacology

Tuesday, March 05 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Tuesday, March 05 | 7:30PM - 10:00PM
Poster Session 2
Room: Breckenridge Ballroom


Wednesday, March 06 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Wednesday, March 06 | 8:00AM - 11:00AM
Physiologically Complex and Realistic Disease Assays
Room: Colorado Ballroom
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.
Speaker 1 of 7
* Tao P. Zhong, East China Normal University, China

Wednesday, March 06 | 8:00AM - 11:00AM
Physiologically Complex and Realistic Disease Assays
Room: Colorado Ballroom
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.
Speaker 2 of 7
Randall T. Peterson, University of Utah, USA
Zebrafish Behaviors as Phenotypes for Neuroactive Compound Discovery

Wednesday, March 06 | 8:00AM - 11:00AM
Physiologically Complex and Realistic Disease Assays
Room: Colorado Ballroom
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.
Speaker 3 of 7
Mark Mercola, Stanford University, USA
High-Throughput Kinetic Studies of iPSC-Derived Cardiomyocytes: Bringing the Patient to the Early Stages of Drug Discovery

Wednesday, March 06 | 8:00AM - 11:00AM
Physiologically Complex and Realistic Disease Assays
Room: Colorado Ballroom
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.

Coffee Break

Wednesday, March 06 | 8:00AM - 11:00AM
Physiologically Complex and Realistic Disease Assays
Room: Colorado Ballroom
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.
Speaker 5 of 7
Neil O. Carragher, University of Edinburgh, UK
Advances in Phenotypic Screening: Accelerating the Discovery of New Chemical Entities and Drug Combinations towards in vivo Proof-of-Concept

Wednesday, March 06 | 8:00AM - 11:00AM
Physiologically Complex and Realistic Disease Assays
Room: Colorado Ballroom
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.
Speaker 6 of 7
Christy Fryer, Novartis Institutes for Biomedical Research, USA
Discovery of a ZIP7 Inhibitor from a Notch Pathway Screen

Wednesday, March 06 | 8:00AM - 11:00AM
Physiologically Complex and Realistic Disease Assays
Room: Colorado Ballroom
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.
Speaker 7 of 7
Kristin Rockwell, Pfizer, USA
Short Talk: Functional Genomics Screening in Primary Human T Cells to Identify Novel Targets for Autoimmune Diseases

Wednesday, March 06 | 11:00AM - 5:00PM
On Own for Lunch


Wednesday, March 06 | 2:30PM - 3:30PM
Workshop: Clinical, Regulatory Case Studies with PDD Project
Prosecution
Room: Colorado Ballroom

Speaker 1 of 4
* Marco Prunotto, F. Hoffmann-La Roche Ltd., Switzerland

Wednesday, March 06 | 2:30PM - 3:30PM
Workshop: Clinical, Regulatory Case Studies with PDD Project
Prosecution
Room: Colorado Ballroom

Speaker 2 of 4
Yevgeny Berdichevsky, Lehigh University, USA
Screen in Organotypic Hippocampal Model of Drug-Resistant Epilepsy Reveals Novel Anticonvulsants

Wednesday, March 06 | 2:30PM - 3:30PM
Workshop: Clinical, Regulatory Case Studies with PDD Project
Prosecution
Room: Colorado Ballroom

Speaker 3 of 4
Herve Tiriac, University of California, San Diego, USA
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Wednesday, March 06 | 2:30PM - 3:30PM
Workshop: Clinical, Regulatory Case Studies with PDD Project
Prosecution
Room: Colorado Ballroom

Speaker 4 of 4
Kerry L. Spear, Blue Oak Pharmaceuticals, USA
Next Generation of Drugs for Bipolar Depression: A Systems Biology Approach

Wednesday, March 06 | 3:30PM - 4:30PM
Panel Discussion
Room: Colorado Ballroom
Panelists to be determined.

Wednesday, March 06 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Wednesday, March 06 | 5:00PM - 7:00PM
Functional Genomics and Systems Approaches
Room: Colorado Ballroom
Functional genomics, machine learning and data mining.
Speaker 1 of 4
* Aravind Subramanian, Broad Institute, USA

Wednesday, March 06 | 5:00PM - 7:00PM
Functional Genomics and Systems Approaches
Room: Colorado Ballroom
Functional genomics, machine learning and data mining.
Speaker 2 of 4
Anna Greka, Harvard Medical School, USA
Toward Targeted, Mechanism-Based Therapies for Kidney Diseases

Wednesday, March 06 | 5:00PM - 7:00PM
Functional Genomics and Systems Approaches
Room: Colorado Ballroom
Functional genomics, machine learning and data mining.
Speaker 3 of 4
Alexandre R. Colas, Sanford-Burnham Medical Research Institute, USA
Novel Single Cell and High-Throughput Phenotypical Platform to Study Atrial Rhythm in hPSCs

Wednesday, March 06 | 5:00PM - 7:00PM
Functional Genomics and Systems Approaches
Room: Colorado Ballroom
Functional genomics, machine learning and data mining.
Speaker 4 of 4
Francisca Vazquez, Broad Institute of Harvard and MIT, USA
Defining a Cancer Dependency Map

Wednesday, March 06 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, March 07 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Thursday, March 07 | 8:00AM - 9:00AM
Keynote Address
Room: Colorado Ballroom

Speaker 1 of 2
* Monica Schenone, Pfizer Inc., USA

Thursday, March 07 | 8:00AM - 9:00AM
Keynote Address
Room: Colorado Ballroom

Speaker 2 of 2
Benjamin F. Cravatt III, The Scripps Research Institute, USA
Activity-Based Proteomics – Protein and Ligand Discovery on a Global Scale

Thursday, March 07 | 9:00AM - 11:30AM
Compound Profiling and Repositioning
Room: Colorado Ballroom

Speaker 1 of 7
* John Moffat, Genentech, Inc., USA

Thursday, March 07 | 9:00AM - 11:30AM
Compound Profiling and Repositioning
Room: Colorado Ballroom

Speaker 2 of 7
Christopher A. Lipinski, Chrstopher A. Lipinski PhD LLC, USA
High-Throughput in vivo Phenotypic Screening for Drug Repurposing: Discovery of MLR-1023, a Novel Insulin Sensitizer and Novel Lyn Kinase Activator with Clinical Proof-of-Concept

Thursday, March 07 | 9:00AM - 11:30AM
Compound Profiling and Repositioning
Room: Colorado Ballroom


Coffee Break

Thursday, March 07 | 9:00AM - 11:30AM
Compound Profiling and Repositioning
Room: Colorado Ballroom

Speaker 4 of 7
Marco Prunotto, F. Hoffmann-La Roche Ltd., Switzerland
Molecular Information Phenotype-Based Drug Discovery: A 5 Year Journey

Thursday, March 07 | 9:00AM - 11:30AM
Compound Profiling and Repositioning
Room: Colorado Ballroom

Speaker 5 of 7
Bruce Posner, University of Texas Southwestern Medical Center, USA
Identifying Subtype-Selective Vulnerabilities and Biomarkers in Non-Small Cell Lung Cancer

Thursday, March 07 | 9:00AM - 11:30AM
Compound Profiling and Repositioning
Room: Colorado Ballroom

Speaker 6 of 7
Mo Mandegar, Tenaya Therapeutics, USA
Short Talk: Artificial Intelligence Accelerates Early-Stage Target and Drug Discovery

Thursday, March 07 | 9:00AM - 11:30AM
Compound Profiling and Repositioning
Room: Colorado Ballroom

Speaker 7 of 7
Christian T. Meyer, Vanderbilt University, USA
Short Talk: A Consensus Framework for Calculating Drug Synergy

Thursday, March 07 | 11:30AM - 5:00PM
On Own for Lunch


Thursday, March 07 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Thursday, March 07 | 5:00PM - 6:45PM
Target Identification / Deconvolution
Room: Colorado Ballroom

Speaker 1 of 5
* Ellen L. Berg, Eurofins DiscoverX, USA

Thursday, March 07 | 5:00PM - 6:45PM
Target Identification / Deconvolution
Room: Colorado Ballroom

Speaker 2 of 5
Dyann F. Wirth, Harvard School of Public Health, USA
Target ID for Malaria

Thursday, March 07 | 5:00PM - 6:45PM
Target Identification / Deconvolution
Room: Colorado Ballroom

Speaker 3 of 5
Bridget Wagner, Broad Institute, USA
The Importance of Phenotypic Screening in Identifying New Targets for Disease Therapeutics

Thursday, March 07 | 5:00PM - 6:45PM
Target Identification / Deconvolution
Room: Colorado Ballroom

Speaker 4 of 5
Herbert Waldmann, Max Planck Institute for Molecular Physiology, Germany
Chemotype – Phenotype - Target

Thursday, March 07 | 5:00PM - 6:45PM
Target Identification / Deconvolution
Room: Colorado Ballroom

Speaker 5 of 5
Heidi Greulich, Broad Institute of MIT and Harvard, USA
Short Talk: PDE3A Modulation for the Treatment of Cancer

Thursday, March 07 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Colorado Ballroom


Thursday, March 07 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Peaks 1-3
No registration fees are used to fund alcohol served at this function.

Thursday, March 07 | 8:00PM - 11:00PM
Entertainment
Room: Peaks 1-3
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 07 | 8:00PM - 11:00PM
Cash Bar
Room: Peaks 1-3


Friday, March 08 | 10:24AM - 10:24AM
Departure


*Session Chair.